// App-Quantinova.ai

P1-04-01 : Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019)

Researchers

Presenter

  • Paoletti C

Principal Investigators

  • Muniz MC

  • Liu M

  • Nanda R

  • Nangia J

  • Storniolo AM

  • Traina TA

  • Vaklavas C

  • Van Poznak CH

  • Wolff AC

  • Forero A

  • Kidwell KM

  • Aung K

  • Thomas DG

  • Brown ME

  • Abramson V

  • Irvin

  • Jr WJ

  • Lin NU

Medical Centers

  • Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN

  • Bon Secours Cancer Institute, Richmon, VA

  • Mayo Clinic, Rochester, MN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Baylor College of Medicine, Houston, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • Melvin and Bren Simon Cancer Center at Indiana University, Indianapolis, IN

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • The University of Chicago Medical Center, Chicago, IL

  • University of Alabama at Birmingham, Birmingham, AL

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Protein-bound paclitaxel

  • Tigatuzumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved